Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2024

05-07-2023 | COVID-19 | Review Article

COVID-19 and β-thalassemia: in lieu of evidence and vague nexus

Authors: Hayder M. Al-Kuraishy, Mohamed H. Mazhar Ashour, Hebatallah M. Saad, Gaber El-Saber Batiha

Published in: Annals of Hematology | Issue 5/2024

Login to get access

Abstract

Coronavirus disease 19 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) causing acute systemic disorders and multi-organ damage. β-thalassemia (β-T) is an autosomal recessive disorder leading to the development of anemia. β-T may lead to complications such as immunological disorders, iron overload, oxidative stress, and endocrinopathy. β-T and associated complications may increase the risk of SARS-CoV-2, as inflammatory disturbances and oxidative stress disorders are linked with COVID-19. Therefore, the objective of the present review was to elucidate the potential link between β-T and COVID-19 regarding the underlying comorbidities. The present review showed that most of the β-T patients with COVID-19 revealed mild to moderate clinical features, and β-T may not be linked with Covid-19 severity. Though patients with transfusion-dependent β-T (TDT) develop less COVID-19 severity compared to non-transfusion-depend β-T(NTDT), preclinical and clinical studies are recommended in this regard.
Literature
1.
Al-Kuraishy HM, Al-Naimi MS, Lungnier CM, Al-Gareeb AI (2020) Macrolides and COVID-19: an optimum premise. Biomedical and Biotechnology Research Journal 4(3):189CrossRef
2.
Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C (2020) Is ivermectin–azithromycin combination the next step for COVID-19? Biomedical and Biotechnology Research Journal 4(5):101CrossRef
3.
Al-Kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C (2020) Renin–angiotensin system and fibrinolytic pathway in COVID-19: one-way skepticism. Biomed Biotechnol Res J 4(5):33CrossRef
4.
Bank S, De SK, Bankura B, Maiti S, Das M, Khan AG (2021) ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases. Biosci Rep 41(2):BSR20202014
5.
Feikin DR, Abu-Raddad LJ, Andrews N, Davies M-A, Higdon MM, Orenstein WA et al (2022) Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine 40(26):3516–3527PubMedPubMedCentralCrossRef
6.
Anjorin AA, Abioye AI, Asowata OE, Soipe A, Kazeem MI, Adesanya IO et al (2021) Comorbidities and the COVID-19 pandemic dynamics in Africa. Tropical Med Int Health 26(1):2–13CrossRef
7.
Al-Kuraishy HM, Al-Gareeb AI (2017) Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia. Asian J Transfus Sci 11(1):13PubMedPubMedCentralCrossRef
8.
Weatherall DJ (2012) The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 26:S3–S6PubMedCrossRef
9.
Amjad F, Fatima T, Fayyaz T, Khan MA, Qadeer MI (2020) Novel genetic therapeutic approaches for modulating the severity of β-thalassemia. Biomed Rep 13(5):1CrossRef
10.
Needs T, Gonzalez-Mosquera LF, Lynch DT (2018) Beta thalassemia. 2022. eng.
11.
Alaithan MA, AbdulAzeez S, Borgio JF (2018) A comprehensive review of the prevalence of beta globin gene variations and the co-inheritance of related gene variants in Saudi Arabians with beta-thalassemia. Saudi Med J 39(4):329PubMedPubMedCentralCrossRef
12.
Pantaleo A, Ferru E, Carta F, Valente E, Pippia P, Turrini F (2012) Effect of heterozygous beta thalassemia on the phosphorylative response to Plasmodium falciparum infection. J Proteome 76:251–258CrossRef
13.
Yasmeen H, Hasnain S (2019) Epidemiology and risk factors of transfusion transmitted infections in thalassemia major: a multicenter study in Pakistan. Hematol Transfus Cell Ther 41:316–323PubMedPubMedCentralCrossRef
14.
Tsai T-A, Tsai C-K, Yang Y-H, Lee Z-M, Sheen J-M, Lee Y-C et al (2020) Higher hospitalization rate for lower airway infection in transfusion-naïve thalassemia children. Front Pediatr 8:574014PubMedPubMedCentralCrossRef
15.
Bonifazi F, Conte R, Baiardi P, Bonifazi D, Felisi M, Giordano P et al (2017) Pattern of complications and burden of disease in patients affected by beta thalassemia major. Curr Med Res Opin 33(8):1525–1533PubMedCrossRef
16.
De Sanctis V, Canatan D, Corrons JLV, Karimi M, Daar S, Kattamis C et al (2020) A comprehensive update of ICET-A network on COVID-19 in thalassemias: what we know and where we stand. Acta Bio Medica: Atenei Parmensis 91(3):e2020026PubMed
17.
Gluba-Brzózka A, Franczyk B, Rysz-Górzyńska M, Rokicki R, Koziarska-Rościszewska M, Rysz J (2021) Pathomechanisms of immunological disturbances in β-thalassemia. Int J Mol Sci 22(18):9677PubMedPubMedCentralCrossRef
18.
Siwaponanan P, Siegers JY, Ghazali R, Ng T, McColl B, Ng GZ-W et al (2017) Reduced PU. 1 expression underlies aberrant neutrophil maturation and function in β-thalassemia mice and patients. Blood, The Journal of the American Society of. Hematology 129(23):3087–3099
19.
Buttari B, Profumo E, Caprari P, Massimi S, Sorrentino F, Maffei L et al (2020) Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia. Ann Hematol 99:2265–2277PubMedCrossRef
20.
Ismabil P (2017) Biochemical and kinetic study on serum adenosine deaminase enzyme in P thalassaemia. Ibn AL-Haitham J Pure Appl Sci 21(2):110–17E
21.
Qin F, Shi L, Li Q, Zhang Z, Liu L, Li J et al (2019) Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children. Eur J Haematol 103(4):342–350PubMedCrossRef
22.
Mahmoud S, Mohamed G, Hakeem G, Higazi A, Nafady A, Farag N et al (2017) Comparison of the immunity status in-between children with [beta]-thalassaemia major receiving different treatment modalities: a single Egyptian district study. Immunome Res 13(1):1
23.
ChD A (2014) Immunologic abnormalities in β-thalassemia. J Blood Disorders Transf 5(224):2
24.
Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127(2):127–139PubMedCrossRef
25.
jyA Yilmaz BA, Demiralp E (2001) Increased plasma levels of interleukin-6 and interleukin-8 in ß-thalassaemia major. Haematologia 31(3):237–244CrossRef
26.
Stolt C, Schmidt IH, Sayfart Y, Steinmetz I, Bast A (2016) Heme oxygenase-1 and carbon monoxide promote Burkholderia pseudomallei infection. J Immunol 197(3):834–846PubMedCrossRef
27.
Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y et al (2020) Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci 7:157PubMedPubMedCentralCrossRef
28.
Ehsanipour F, Faranoush P, Foroughi-Gilvaee MR, Sadighnia N, Fallahpour M, Motamedi M et al (2022) Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study. Health Sci Rep 5(6):e871PubMedPubMedCentralCrossRef
29.
Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F et al (2020) Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol 146(1):119–27.e4PubMedPubMedCentralCrossRef
30.
Al-Hakeim HK, Najm AH, Al-Dujaili AH, Maes M (2020) Major depression in children with transfusion-dependent thalassemia is strongly associated with the combined effects of blood transfusion rate, iron overload, and increased pro-inflammatory cytokines. Neurotox Res 38:228–241PubMedCrossRef
31.
32.
Karimi M, Haghpanah S, Azarkeivan A, Zahedi Z, Zarei T, Akhavan Tavakoli M et al (2020) Prevalence and mortality due to outbreak of novel coronavirus disease (COVID-19) in β-Thalassemias: the Nationwide Iranian experience. Available at SSRN 3605175
33.
Karimi M, De Sanctis V (2020) Implications of SARSr-CoV 2 infection in thalassemias: do patients fall into the “high clinical risk” category? Acta Bio Medica: Atenei Parmensis 91(2):50PubMed
34.
Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395(10223):473–475PubMedPubMedCentralCrossRef
35.
Longo F, Gianesin B, Voi V, Motta I, Pinto VM, Piolatto A et al (2022) Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection. Am J Hematol 97(2):E75–EE8PubMedCrossRef
36.
Sotiriou S, Samara AA, Vamvakopoulou D, Vamvakopoulos K-O, Sidiropoulos A, Vamvakopoulos N et al (2021) Susceptibility of β-thalassemia heterozygotes to COVID-19. J Clin Med 10(16):3645PubMedPubMedCentralCrossRef
37.
Sotiriou S, Samara AA, Lachanas KE, Vamvakopoulou D, Vamvakopoulos K-O, Vamvakopoulos N et al (2022) Vulnerability of β-thalassemia heterozygotes to COVID-19: results from a cohort study. J Pers Med 12(3):352PubMedPubMedCentralCrossRef
38.
39.
Pinto VM, Derchi GE, Bacigalupo L, Pontali E, Forni GL (2020) COVID-19 in a patient with β-thalassemia major and severe pulmonary arterial hypertension. Hemoglobin 44(3):218–220PubMedCrossRef
40.
41.
DeMartino AW, Rose JJ, Amdahl MB, Dent MR, Shah FA, Bain W et al (2020) No evidence of hemoglobin damage by SARS-CoV-2 infection. Haematologica 105(12):2769PubMedPubMedCentralCrossRef
42.
Shokrgozar N, Amirian N, Ranjbaran R, Bazrafshan A, Sharifzadeh S (2020) Evaluation of regulatory T cells frequency and FoxP3/GDF-15 gene expression in β-thalassemia major patients with and without alloantibody; correlation with serum ferritin and folate levels. Ann Hematol 99:421–429PubMedCrossRef
43.
44.
Liu Y, Qi G, Bellanti JA, Moser R, Ryffel B, Zheng SG (2020) Regulatory T cells: a potential weapon to combat COVID-19? Med Comm 1(2):157–164
45.
46.
Novák P, Jackson AO, Zhao G-J, Yin K (2020) Bilirubin in metabolic syndrome and associated inflammatory diseases: new perspectives. Life Sci 257:118032PubMedCrossRef
47.
Leem AY, Kim YS, Lee J-H, Kim T-H, Kim HY, Oh YM et al (2019) Serum bilirubin level is associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. Respir Res 20(1):1–8CrossRef
48.
Santangelo R, Mancuso C, Marchetti S, Di Stasio E, Pani G, Fadda G (2012) Bilirubin: an endogenous molecule with antiviral activity in vitro. Front Pharmacol 3:36PubMedPubMedCentralCrossRef
49.
Lin Y, Wang S, Yang Z, Gao L, Zhou Z, Yu P et al (2019) Bilirubin alleviates alum–induced peritonitis through inactivation of NLRP3 inflammasome. Biomed Pharmacother 116:108973PubMedCrossRef
50.
Shaw J, Chakraborty A, Nag A, Chattopadyay A, Dasgupta AK, Bhattacharyya M (2017) Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients. Eur J Haematol 99(5):399–408PubMedCrossRef
51.
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018) Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol 14(10):576–590PubMedCrossRef
52.
Ghatreh-Samani M, Esmaeili N, Soleimani M, Asadi-Samani M, Ghatreh-Samani K, Shirzad H (2016) Oxidative stress and age-related changes in T cells: is thalassemia a model of accelerated immune system aging? Cent Eur J Immunol 41(1):116–124PubMedPubMedCentralCrossRef
53.
Fulop T, Witkowski JM, Olivieri F, Larbi A (2018) The integration of inflammaging in age-related diseases. Semin Immunol 2018:17–35CrossRef
54.
Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA et al (2018) Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol 8:1960PubMedPubMedCentralCrossRef
55.
Pietrobon AJ, Teixeira FME, Sato MN (2020) I mmunosenescence and inflammaging: risk factors of severe COVID-19 in older people. Front Immunol 11:579220PubMedPubMedCentralCrossRef
56.
d'Arqom A, Putri GM, Savitri Y, Rahul Alfaidin AM (2020) Vitamin and mineral supplementation for β-thalassemia during COVID-19 pandemic. Future Sci OA 6(9):FSO628PubMedPubMedCentralCrossRef
57.
Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S (2020) Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol 11:1949PubMedPubMedCentralCrossRef
58.
Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A et al (2010) Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 95(8):1308PubMedPubMedCentralCrossRef
59.
Karunaratna AMDS, Ranasingha JGS, Mudiyanse RM (2018) Zinc status in beta thalassemia major patients. Biol Trace Elem Res 184:1–6PubMedCrossRef
60.
Alhillawi ZH, Al-Hakeim HK, Moustafa SR, Maes M (2021) Increased zinc and albumin but lowered copper in children with transfusion-dependent thalassemia. J Trace Elem Med Biol 65:126713PubMedCrossRef
61.
Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI et al (2020) Zinc and respiratory tract infections: perspectives for COVID-19. Int J Mol Med 46(1):17–26PubMedPubMedCentral
62.
Jothimani D, Kailasam E, Danielraj S, Nallathambi B, Ramachandran H, Sekar P et al (2020) COVID-19: poor outcomes in patients with zinc deficiency. Int J Infect Dis 100:343–349PubMedPubMedCentralCrossRef
63.
Ayyash H, Sirdah M (2018) Hematological and biochemical evaluation of β-thalassemia major (βTM) patients in Gaza strip: a cross-sectional study. Int J Health Sci 12(6):18
64.
Levin C, Koren A, Rebibo-Sabbah A, Koifman N, Brenner B, Aharon A (2018) Extracellular vesicle characteristics in β-thalassemia as potential biomarkers for spleen functional status and ineffective erythropoiesis. Front Physiol 9:1214PubMedPubMedCentralCrossRef
65.
Chang L, Zhao L, Gong H, Wang L, Wang L (2020) Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations. Emerg Infect Dis 26(7):1631PubMedPubMedCentralCrossRef
66.
Lee C, Leung JS, Cheng P, Lung D, To K, Tsang D (2021) Absence of SARS-CoV-2 viraemia in a blood donor with COVID-19 post-donation. Transfus Med 31(3):223PubMedCrossRef
67.
Moafa W, Aldhamdi N, Alhazmi S, Gohal G, Moafa W, Alhazmi A (2022) Covid-19 in patients with sickle cell disease. Egypt J Haematol 47(1):11CrossRef
68.
Del Campo PL, de Paz AR, López AR, de la Cruz BB, Barbier KH, Vadillo IS et al (2020) No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19. Transfus Apher Sci 59(6):102921CrossRef
69.
Habib HM, Ibrahim S, Zaim A, Ibrahim WH (2021) The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed Pharmacother 136:111228PubMedPubMedCentralCrossRef
70.
Del Nonno F, Nardacci R, Colombo D, Visco-Comandini U, Cicalini S, Antinori A et al (2021) Hepatic failure in COVID-19: is iron overload the dangerous trigger? Cells 10(5):1103PubMedPubMedCentralCrossRef
71.
Karimi M, Haghpanah S, Zarei T, Azarkeivan A, Shirkavand A, Matin S et al (2020) Prevalence and severity of coronavirus disease 2019 (COVID-19) in transfusion dependent and non-transfusion dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study. Acta Bio Medica: Atenei Parmensis 91(3):e2020007PubMed
72.
73.
Lee JX, Chieng WK, Lau SCD, Tan CE (2021) COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med 8:757510CrossRef
74.
Ruscitti P, Berardicurti O, Barile A, Cipriani P, Shoenfeld Y, Iagnocco A et al (2020) Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? Ann Rheum Dis 79(11):1515–1516PubMedCrossRef
75.
Haghpanah S, Hosseini-Bensenjan M, Sayadi M, Karimi M (2021) Incidence rate of COVID-19 infection in hemoglobinopathies: a systematic review and meta-analysis. Hemoglobin 45(6):371–379PubMedCrossRef
76.
De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M et al (2013) Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab 17(1):8PubMedPubMedCentralCrossRef
77.
78.
Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A (2014) Guidelines for diagnosis and management of beta-thalassemia intermedia. Pediatr Hematol Oncol 31(7):583–596PubMedCrossRef
79.
Bergamaschi G, Borrelli de Andreis F, Aronico N, Lenti MV, Barteselli C, Merli S et al (2021) Anemia in patients with Covid-19: pathogenesis and clinical significance. Clin Exp Med 21(2):239–246PubMedPubMedCentralCrossRef
80.
Sposi NM (2019) Oxidative stress and iron overload in β-thalassemia: an overview. Beta Thalassemia 3:40–51
81.
82.
Gharagozloo M, Bagherpour B, Tahanian M, Oreizy F, Amirghofran Z, Sadeghi HMM et al (2009) Premature senescence of T lymphocytes from patients with β-thalassemia major. Immunol Lett 122(1):84–88PubMedCrossRef
83.
84.
Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z et al (2020) Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging 12(13):12493PubMedPubMedCentralCrossRef
85.
Okar L, Ali M, Parengal J, Yassin MA (2020) COVID-19 and thalassemia beta major in splenectomized patient: clinical case progression and literature review. Clin Case Rep 8(12):2917–2921CrossRef
86.
87.
Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M, Mulet S et al (2020) Oxidative stress and inflammation in COVID-19-associated sepsis: the potential role of anti-oxidant therapy in avoiding disease progression. Antioxidants 9(10):936PubMedPubMedCentralCrossRef
88.
Silvagno F, Vernone A, Pescarmona GP (2020) The role of glutathione in protecting against the severe inflammatory response triggered by COVID-19. Antioxidants 9(7):624PubMedPubMedCentralCrossRef
89.
Nasseri E, Mohammadi E, Tamaddoni A, Qujeq D, Zayeri F, Zand H (2017) Benefits of curcumin supplementation on antioxidant status in β-thalassemia major patients: a double-blind randomized controlled clinical trial. Ann Nutr Metab 71(3-4):136–144PubMedCrossRef
90.
Raducka-Jaszul O, Bogusławska DM, Jędruchniewicz N, Sikorski AF (2020) Role of extrinsic apoptotic signaling pathway during definitive erythropoiesis in normal patients and in patients with β-thalassemia. Int J Mol Sci 21(9):3325PubMedPubMedCentralCrossRef
91.
92.
He L-N, Chen W, Yang Y, Xie Y-J, Xiong Z-Y, Chen D-Y et al (2019) Elevated prevalence of abnormal glucose metabolism and other endocrine disorders in patients with-thalassemia major: a meta-analysis. Biomed Res Int 2019:1–13
93.
Mula-Abed W-A, Al Hashmi H, Al Muslahi M, Al Muslahi H, Al Lamki M (2008) Prevalence of endocrinopathies in patients with beta-thalassaemia major-a cross-sectional study in Oman. Oman Med J 23(4):257PubMedPubMedCentral
94.
Abdul-Hadi MH, Naji MT, Shams HA, Sami OM, Al-Harchan NA-A, Al-Kuraishy HM et al (2020) Oxidative stress injury and glucolipotoxicity in type 2 diabetes mellitus: the potential role of metformin and sitagliptin. Biomedical and Biotechnology Research Journal 4(2):166CrossRef
95.
Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C et al (2020) Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care 43(7):1382–1391PubMedCrossRef
96.
Li Y, Han X, Alwalid O, Cui Y, Cao Y, Liu J et al (2020) Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: a retrospective study. Diabetes Res Clin Pract 166:108299PubMedPubMedCentralCrossRef
97.
Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi E et al (2020) Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic hospital in Lombardy, Italy. Diabetes Care 43(12):3042–3049PubMedCrossRef
98.
Frydrych LM, Bian G, O’Lone DE, Ward PA, Delano MJ (2018) Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol 104(3):525–534PubMedCrossRef
99.
Finucane FM, Davenport C (2020) Coronavirus and obesity: could insulin resistance mediate the severity of Covid-19 infection? Front Public Health 8:184PubMedPubMedCentralCrossRef
100.
Valk T, McMorrow C (2020) Managing hyperglycemia during the COVID-19 pandemic: improving outcomes using new technologies in intensive care. SAGE Open Med 8:2050312120974174PubMedPubMedCentralCrossRef
101.
Çayan S, Uğuz M, Saylam B, Akbay E (2020) Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study. Aging Male 23(5):1493–1503PubMedCrossRef
102.
Teixeira TA, Oliveira YC, Bernardes FS, Kallas EG, Duarte-Neto AN, Esteves SC et al (2021) Viral infections and implications for male reproductive health. Asian J Androl 23(4):335PubMedPubMedCentralCrossRef
103.
De Sanctis V, Soliman AT, Yassin MA, Di Maio S, Daar S, Elsedfy H et al (2018) Hypogonadism in male thalassemia major patients: pathophysiology, diagnosis and treatment. Acta Bio Medica: Atenei Parmensis 89(Suppl 2):6PubMed
104.
Adiwinoto RD, Pranoto A, Prayogo AA, Soelistijo SA (2020) Low total testosterone levels in adult male thalassemia major patients: an overlooked complication of iron overload. EurAsian J BioSci 14(1):2461–2466
105.
106.
Paul A, Thomson VS, Refaat M, Al-Rawahi B, Taher A, Nadar SK (2019) Cardiac involvement in beta-thalassaemia: current treatment strategies. Postgrad Med 131(4):261–267PubMedCrossRef
107.
Derchi G, Dessì C, Bina P, Cappellini MD, Piga A, Perrotta S et al (2019) Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Intern Emerg Med 14:365–370PubMedCrossRef
108.
Aghagoli G, Gallo Marin B, Soliman LB, Sellke FW (2020) Cardiac involvement in COVID-19 patients: risk factors, predictors, and complications: a review. J Card Surg 35(6):1302–1305PubMedPubMedCentralCrossRef
109.
Imazio M, Klingel K, Kindermann I, Brucato A, De Rosa FG, Adler Y et al (2020) COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis? Heart 106(15):1127–1131PubMedCrossRef
110.
Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, Usui S-i et al (2002) Iron overload augments angiotensin II–induced cardiac fibrosis and promotes neointima formation. Circulation 106(14):1840–1846PubMedCrossRef
111.
Mahdi LS, Faraj SA, Ghali HH (2015) Significance of red blood cell indices in beta-thalassaemia trait. Mustansiriya Med J 14(2):27
112.
Batiha GE-S, Gari A, Elshony N, Shaheen HM, Abubakar MB, Adeyemi SB et al (2021) Hypertension and its management in COVID-19 patients: the assorted view. Inter J Cardiol Cardiovasc Risk Prev 11:200121
Metadata
Title
COVID-19 and β-thalassemia: in lieu of evidence and vague nexus
Authors
Hayder M. Al-Kuraishy
Mohamed H. Mazhar Ashour
Hebatallah M. Saad
Gaber El-Saber Batiha
Publication date
05-07-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05346-8

Other articles of this Issue 5/2024

Annals of Hematology 5/2024 Go to the issue

Case Report

Adult type I Gaucher disease with splenectomy caused by a compound heterozygous GBA1 mutation in a Chinese patient: a case report

Original Article

Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape

Correction

Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia

Original Article

Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell mobilization

Original Article

Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience

Research

Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits